Correlative imaging of hypoxia and angiogenesis in oncology

Journal of Nuclear Medicine

Volumn 49, Issue 4, 2008, Pages 515-516

  Langen, Karl Josef ^a   Eschmann, Susanne Martina ^b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b MARIENHOSPITAL STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; IODINE 124; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANGIOGENESIS; DRUG BINDING; DRUG UPTAKE; HYPOXIA; IMAGING; NONHUMAN; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; SHORT SURVEY; TUMOR DIAGNOSIS;

AUTORADIOGRAPHY; CELL HYPOXIA; GLUCOSIDES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITROIMIDAZOLES; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY;

EID: 42049106234     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.050559     Document Type: Short Survey

References (22)

1. Horsman MR, Overgaard J. The oxygen effect and tumour microenvironment. In: Steel GG, ed. Basic Clinical Radiobiology. London, U.K.: Arnold; 2002:158-168.
2. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007;26:281-290.
3. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9:677-684.
4. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res. 2007;13:5670-5674.
5. Diaz-Gonzalez JA, Russell J, Rouzaut A, Gil-Bazo I, Montuenga L. Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther. 2005;4:1055-1062.
6. Lyseng-Williamson KA, Robinson DM. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs. 2006;20:193-195.
7. 125I-gluco-RGD autoradiography. J Nucl Med. 2008;49:597-605.
8. 18F- galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.
9. 18F-FDG. J Nucl Med. 2008;49:22-29.
10. 18F-fluoromisonidazole. Semin Nucl Med. 2007;37:451-461.
11. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-260.
12. 18F-misonidazole and PET: changes of kinetics during radiotherapy of headand-neck cancer. Radiother Oncol. 2007;83:406-410.
13. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer. 2005;5:152.
14. 18F-labelled tracers: biology meets technology. Eur J Nucl Med Mol Imaging. 2007;34:1563-1565.
15. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003;30:317-326.
16. 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106-113.
17. 18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34:1566-1575.
18. Grosu AL, Souvatzoglou M, Röper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 1;69:541-551.
19. 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48:973-980.
20. Haubner R. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging. 2006;33(suppl 1):54-63.
21. Haubner R, Wester HJ, Reuning U, et al. Radio-labeled alphavbeta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061-1071.
22. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002;8:918-921.